NCT02326441已完成1 期
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 3
- 主要终点
- Define MTD
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of the study drug KX2-361 and to determine how much of the study drug enters the bloodstream, in patients with advanced malignancies that have not responded to conventional therapies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent.
- •Adults ≥ 18 years of age.
- •Dose Escalation Cohort only:
- •Confirmed advanced solid tumor or lymphoma for which standard curative or palliative measures do not exist or are no longer effective; subjects with progressive brain metastases are also eligible.
- •OR Confirmed Histological/cytological hematological malignancy that is refractory to/relapsed after and/or intolerant of standard therapies or for which no standard therapy exists.
- •OR Confirmed high grade glioma (grade 3and4) that is relapsed/refractory to standard therapies and who have progressive disease following radiation therapy. Patients with any number of prior treatments are allowed.
- •Expansion Cohort only:
- •Patients with high grade glioma (grade 3 and 4) that are refractory to standard therapies, and who have progressive disease following radiation therapy. Patients with any number of prior treatments are allowed.
- •ECOG performance status of 0-2, Karnofsky Performance Status ≥60 (for glioma subjects).
- •Life expectancy of at least 12 weeks.
- •The following laboratory values:
- •ANC ≥ 1.5 x 10⁹/L
- •Platelets ≥ 100 x 10⁹/L
- •Hemoglobin (Hgb) > 10 g/dL
- •Serum total bilirubin ≤ 1.5 x ULN
- •ALT and AST ≤ 3.0 x ULN (subjects with known liver metastases may have AST and ALT ≤ 5.0 x ULN)
- •Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance (using Cockcroft and Gault method) > 60 mL/min)
- •Willingness to use acceptable birth control. Subjects with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Female subjects of child-bearing potential must have a negative pregnancy test.
排除标准
- •Subjects who have not recovered to Grade 0 or 1 toxicity from previous anti-cancer treatments or previous investigational agents.
- •Subjects who have received investigational agents within 28 days of the first day of study drug.
- •Subjects with primary CNS malignancy other than high grade glioma (Grade 3 or 4)
- •Subjects who have received extensive radiation therapy, including sternum, pelvis, scapulae, vertebrae or skull, within 4 weeks of the first day of study drug or received palliative low dose radiation therapy limited to limbs within 1 week of the first day of study drug, or subjects who have not recovered from side effects of such therapy.
- •Subjects who are currently taking or have received hormones (eg, estrogen or progesterone) within 7 days the first dose of study drug. Note: Luteinizing hormone-releasing hormone (LHRH) analogs are permissible.
- •Subjects who are using moderate or strong CYP450 3A4 modulators (with the exception of antifungal agents listed in Appendix 2) within 5 half-lives before the first dose of study drug.
- •Subjects who are using prescription or OTC medications (including, for example, proton pump inhibitors, H2 antagonists or calcium carbonate) that reduce or neutralize gastric acidity within 5 half lives before the first dose of study drug. Use of these medications for supportive care after cycle 1 is permitted.
- •Subjects who had major surgery within 4 weeks of the first day of study drug.
- •Subjects who had major surgery to the upper gastrointestinal tract, or who have a history of inflammatory bowel disease, malabsorption syndrome, or other medical condition that may interfere with oral drug absorption.
- •Subjects with a history of intestinal perforation, colitis, clinically significant gastrointestinal bleeding or intestinal obstruction within one year prior to enrollment.
- •Subjects with signs or symptoms of other major diseases including, but not limited to: end organ failure, major chronic illnesses other than cancer, coagulation disorders, hemolytic conditions (eg, sickle cell disease ) or active infections that, in the opinion of the investigator, make it undesirable for the subject to participate in the study.
- •Subjects who have a history of major cardiac or neurologic disease including, but not limited to, angina pectoris, symptomatic coronary artery disease, uncontrolled hypertension (at time of study entry), New York Heart Association (NYHA) Class III or IV congestive heart failure, confirmed significant cardiac conduction abnormalities (including QTc > 0.45 sec) or arrhythmias, myocardial infarction within 12 months, cerebrovascular accidents, or transient ischemic attacks.
- •Other conditions which could jeopardize the subject's ability to comply with the protocol including but not limited to dementia, psychosis, or other major psychiatric disorder.
- •Subjects with a known history of hepatitis B or C or human immunodeficiency (HIV) infection.
- •Subjects who require therapeutic doses of anticoagulants.
- •Subjects who require the use of granulocyte colony stimulating factors (GCSF) for prophylaxis of neutropenia.
研究组 & 干预措施
KX2-361
Experimental
干预措施: KX2-361 (Drug)
结局指标
主要结局
Define MTD
时间窗: 12 months
The Maximum Tolerated Dose is defined as one dose level below where two or more subjects experienced a dose limiting toxicity (DLT).
次要结局
- Safety and Tolerability assessed by adverse events and changes in laboratory parameters(24 months)
- Activity in escalation and expansion cohorts (according to the RECIST criteria, CHESON criteria, or the Modified RANO)(24 months)
- Pharmacokinetics (rofile pharmacokinetic outcome measures, e.g. Cmax, Tmax, AUCt, AUC0-inf, t½, CL, and Css)(24 months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic KeratosisActinic KeratosisNCT02337205Athenex, Inc.29
Unknown
1 期
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast CancerChemotherapy-induced NeutropeniaNCT02725606Jiangsu T-Mab Biopharma Co.,Ltd30
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic InsufficiencySafety, Tolerability, and PK of NBI-98854 in Hepatically Impaired SubjectsNCT01916993Neurocrine Biosciences24
Unknown
1 期
A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis PatientsRheumatoid ArthritisNCT04179513Genor Biopharma Co., Ltd.24
已完成
1 期
Study to Assess PK, Safety and Tolerability in Healthy SubjectsAcute Ischemic StrokeNCT06380699Changzhou Qianhong Bio-pharma Co., Ltd.56